CREATIVE MEDICAL TECHNOLOGY
CELZNASDAQTrading Snapshot
- Day Range
- $0.99 – $1.02
- 52-Week Range
- $0.62 – $6.25
- Volume
- $2.61B
- Avg Volume
- $3.05B
- Shares Outstanding
- 2.6M
- Next Earnings
- Dec 4, 2026
Fundamentals Snapshot
- Annual Revenue
- $6,000
- Last Q Revenue
- $1,355
- P/E Ratio
- -0.5
- P/S Ratio
- 860.2x
- EPS (TTM)
- $-1.63
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +44.3%
Why Investors Own CELZ
- ✓High-growth profile — revenue up +7.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 57% gross margin and 30% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
CREATIVE MEDICAL TECHNOLOGY
CELZ
StockOtter · stockotter.spaceAbout CREATIVE MEDICAL TECHNOLOGY
Creative Medical Technology Holdings, Inc., a biotechnology firm based in Phoenix, Arizona, specializes in advancing adult stem cell treatments. The company's core focus spans several medical fields, including immunology, urology, orthopedics, and neurology. Among its therapeutic offerings are CaverStem, designed to address erectile dysfunction; FemCelz, which aims to restore genital sensitivity and alleviate dryness; StemSpine, developed to treat chronic lower back pain; ImmCelz, intended for stroke patients; and OvaStem, a solution for female infertility.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Creative Medical Technology (NASDAQ:CELZ) & argenex (NASDAQ:ARGX) Head to Head Analysis
argenex (NASDAQ: ARGX - Get Free Report) and Creative Medical Technology (NASDAQ: CELZ - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the stre
Creative Medical Technology Holdings, Inc. Expands Ultrasome™ Intellectual Property Portfolio with New U.S. Provisional Patent Filing
PHOENIX, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative medicine solution
Critical Contrast: Creative Medical Technology (NASDAQ:CELZ) vs. CRISPR Therapeutics (NASDAQ:CRSP)
Creative Medical Technology (NASDAQ: CELZ - Get Free Report) and CRISPR Therapeutics (NASDAQ: CRSP - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses
Creative Medical Technology Holdings Successfully Completes Enrollment and Treatment Across Entire FDA-Cleared ADAPT Trial, Including Opioid Cohort, Advancing CELZ-201 / Olastrocel Toward RMAT Evaluation and Phase 3 Planning
All patients enrolled and treated across original and FDA-cleared expansion cohorts Positive safety and early efficacy signals continue to support late-stage development planning for Olastrocel in chronic lower back pain
Creative Medical Technology Stock Surges After Key Patent Win
Creative Medical Technology Holdings Inc. (NASDAQ:CELZ) shares are surging Thursday afternoon following an intellectual property milestone.
Creative Medical Technology Holdings, Inc. Receives Notice of Allowance for New U.S. Patent Covering Exosome-Based Immunotherapy for Type 1 Diabetes, Deepening IP Protection Across Its MyeloCelz™, CELZ-101 and CELZ-201 Diabetes Platforms
Newly Allowed Patent Protects Cell-Free MyeloCelz™ Exosome Technology Designed to Suppress Autoimmune Destruction of Insulin-Producing Cells, Reinforcing Creative Medical's Multi-Program Diabetes Strategy Newly Allowed P